A prospective clinical trial to assess the role of Homoeopathic medicine Terminalia arjuna and Guatteria Gaumeri in reducing lipid level in body

Comparative evaluation of the effectiveness of Terminalia arjuna and Guatteria gaumeri in the management of dyslipidemia: A randomized controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/12/077955

Enrollment

100

Registered

2024-12-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E780- Pure hypercholesterolemia Health Condition 2: E781- Pure hyperglyceridemia Health Condition 3: E782- Mixed hyperlipidemia Health Condition 4: E783- Hyperchylomicronemia Health Condition 5: E784- Other hyperlipidemia Health Condition 6: E786- Lipoprotein deficiency Health Condition 7: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: Terminalia arjuna: 4 gobules in size 30 for three times a day for three months Control Intervention1: Guatteria gaumeri: 4 gobules in size 30 for three times a day for three months

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of Dyslipidemia: Participants must have a confirmed diagnosis of dyslipidemia, characterized by abnormal lipid levels. 2. Age Group: Adults aged 18-65 years of both sexes. 4. Willingness to Participate: Participants must be willing to follow the study protocol, attend follow-up visits, and adhere to the prescribed treatment (either Terminalia Arjuna or Guatteria Gaumeri). 5. Signed Informed Consent

Exclusion criteria

Exclusion criteria: 1. Severe Cardiovascular Conditions with a history of recent cardiovascular events within the last six months. 2. Existing Treatment for Dyslipidemia: Patients who are currently on any other lipid-lowering medications (e.g., statins, fibrates) and unwilling to discontinue or who cannot discontinue for medical reasons. 3. Chronic Liver or Kidney Disease: Individuals with severe liver disease or renal insufficiency, as these conditions could interfere with lipid metabolism or the safety of the remedies. 4. Pregnancy or Lactation. 5. Use of Alternative or Complementary Medicines: Patients using other herbal or alternative treatments that may interfere with lipid levels. 6. Severe Mental Health Conditions: Individuals with unmanaged psychiatric conditions that may impact adherence to the study protocol or affect their ability to give informed consent.

Design outcomes

Primary

Measure	Time frame
Percent reduction in lipid levels from baselineline score after interventionTimepoint: 3 months after intervention	—

Secondary

Measure	Time frame
Weight loss,Timepoint: 3 months after intervention	—

Countries

India

Contacts

Public ContactNipun Singh Dabi

Swasthya Kalyan Homoeopathic Medical College and Research Centre

thebarjagdish@gmail.com9829391362

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026